Objective: Pediatric colonic eosinophilia represents a confounding finding with a wide differential. It is often difficult to determine which children may progress to inflammatory bowel disease (IBD), which have an eosinophilic colitis (EC), and which may have no underlying pathology. There is little guidance for the practitioner on the approach to these patients. To define the clinical presentations of colonic eosinophilia and identify factors which may aid in diagnosis we reviewed patients with colonic eosinophilia and the clinicopathologic factors associated with their diagnoses. Methods: An 8-year retrospective chart review of children whose histopathology identified colonic eosinophilia (N ¼ 72) compared to controls with normal biopsies (N ¼ 35). Results: Patients with colonic eosinophilia had increased eosinophils/highpower field compared to controls (P < 0.001) and had 3 clinical phenotypes. Thirty-six percent had an inflammatory phenotype with elevated erythrocyte sedimentation rate (P < .0001), chronic inflammation on colonic biopsies (P < 0.001), and were diagnosed as having IBD. Thirty-seven percent were diagnosed as having EC, associated with male sex (P < 0.005) and peripheral eosinophilia (P ¼ 0.041). Twenty-one percent had no significant colonic pathology. Forty-three percent of patients had >1 colonoscopy and 68% of these had change from initial diagnoses. Conclusions: There are 3 main phenotypes of children with colonic eosinophilia. Signs of chronic systemic inflammation raise suspicion for IBD. Peripheral eosinophilia and male sex are associated with EC. A significant percent of children with colonic eosinophilia do not have colonic disease. Eosinophils/high-power field is not reliable to differentiate etiologies. Repeat colonoscopies may be required to reach final diagnoses.
C olonic eosinophilia represents a challenging histological feature observed in some pediatric patients undergoing evaluation for common gastrointestinal complaints. Pathological guidelines distinguishing normal from abnormal numbers of colonic eosinophilia are scarce and have found variable results with mean maximum eosinophils/high-powered field (eos/HPF) in the cecum from 14 to 47 (1) (2) (3) (4) in normal children, and geographic variation has been described as well (5) . Little is known about the prognosis or pathogenesis of this finding in the absence of some clear causes such as parasitic infection, drug reaction, bone marrow transplant, collagen vascular disease, radiation treatment, or constipation (6) .
Children and adolescents with colonic eosinophilia often do not respond to dietary restriction (7) suggesting that food allergy is not the primary driver of colonic eosinophilia in these patients. In infants, however, colonic eosinophilia appears to have a defined allergic reaction (8, 9) . Clinical experiences suggest that colonic eosinophilia may be a subset of inflammatory bowel disease (IBD) (10) (11) (12) (13) . Other studies describe colonic eosinophilia as preceding (11) or overlapping (14) the diagnosis of IBD, yet this has not been well defined (15) . Another group of patients with colonic eosinophilia, without evidence of IBD or other known cause, has been described and termed eosinophilic colitis (EC). Adult series suggest EC can be either a self-limited condition or have a waxing and waning course (16) . Significant difficulties arise in differentiating EC from IBD, as they can present with similar symptoms. Previous studies have not delineated clinicopathologic factors, which may help the clinician to distinguish between this diverse group of diseases.
What Is Known
Colonic eosinophilia in pediatrics is not well defined. Peak number of eosinophils is variable thus not diagnostic. Inflammatory bowel disases has been associated with eosinophilia.
What Is New
Three phenotypes of colonic eosinophilia are identified. Association of age, sex, and chronic disease with colonic eosinophilia. Need for repeat colonoscopy to define diagnosis.
To better understand the clinical ramifications of colonic eosinophilia, we performed a retrospective analysis of children seen at a single institution who had an initial pathological report of ''colonic eosinophilia.'' The aims of our study were: to compare control colon biopsies to patients with colonic eosinophilia to better define colonic eosinophilia, to delineate clinicopathologic factors which may help identify patients with IBD versus EC versus other diagnoses, and to determine whether repeat colonoscopy clarified the diagnoses.
METHODS

Subject Selection
A search of the Children's Hospital Colorado Department of Pathology database from 2006 to 2013 was conducted using the search terms ''Colonic eosinophilia,'' ''Eosinophilic colitis,'' ''Eosinophilia,'' or ''Increased Eosinophils.'' Because there is no agreed upon definition for normal versus abnormal numbers of eosinophils in the pediatric colon, we did not use a specific number cutoff of eosinophils to select subjects but instead reviewed all records in which pathologist's interpretation was stated to be one of these above terms. We identified this cohort as having ''colonic eosinophilia. '' A similar search of the Children's Hospital Colorado Department of Pathology database was conducted to identify controls. These control subjects were previously identified at our institution (17) , had common symptoms of gastrointestinal (GI) dysfunction (abdominal pain, diarrhea, concern for juvenile polyp). They underwent upper endoscopy and colonoscopy without endoscopic or histologic pathology (except juvenile polyp), without mention of increased eosinophils or any features of acute or chronic inflammation. There was no evidence of elevated inflammatory markers (erythrocyte sedimentation rate [ESR], CRP), anemia or history of any use of medications likely to alter eosinophil numbers in the colon (systemic steroids, 5-aminosalicylates, immunomodulators, biologic therapies, or antibiotics). We termed this cohort ''controls.'' Electronic medical records review identified clinical features of control subjects and those with colonic eosinophilia, which included demographics, symptoms, laboratory testing, endoscopic findings, and final diagnoses.
Ulcerative colitis, Crohn disease (CD), and indeterminate colitis were combined for a diagnosis of ''Any IBD'' and separated into discrete categories. Laboratory studies performed within 1 month of colonoscopy were included in analysis.
Exclusion criteria included: under 1 year of age at initial biopsy-diagnoses of allergic colitis, bone marrow transplant, or parasitic infection. This study was approved by the institutional review board at the University of Colorado.
Specimen Histological Assessments
All hematoxylin and eosin-stained colonic tissue sections from ''colonic eosinophilia'' subjects were assessed by a board certified pediatric pathologist (K.C.). Signs of chronic inflammation on histopathology were identified by the pathologist (K.C.) when distorted gland architecture, multiple branched glands, Paneth cells in the left colon, and/or fibrosis were present. Entire specimens were reviewed and the area with highest eosinophil density was selected to enumerate peak number of eosinophils/high powered field (eos/HPF) at Â40 magnification field size of 0.26 mm 2 . Colonic biopsies from control subjects were evaluated in a similar fashion by the pathologist (K.C.) as well as 4 independent observers (E.D., J.M., J.M., S.F.). Using 92 pathological slides from 35 controls, interobserver reliability between these observers and K.C. was evaluated by pair-wise Bland-Altman plot analysis. Intraclass correlation coefficient was greater than 0.85 suggesting strong agreement.
Statistical Analysis SAS 9.4 (SAS Institute Inc., Cary, NC) was used for all the analyses. Associations of max eos/HPF with other continuous variables were assessed using spearman correlation. Two independent sample t test and x 2 test were used respectively to compare continuous and categorical outcomes between controls and patients with eosinophilia and between patients with and those without IBD diagnosis. A linear mixed-effects model with unstructured covariance was used to compare max eos across 3 segments of colon and between patients with and without IBD. P value <0.05 was deemed to be significant.
RESULTS
Patient Demographics and History
Review of our pathology database identified 78 patients with colonic eosinophilia. Six were not included based on exclusion criteria. Comparison of colonic eosinophilia patients to controls revealed that they were younger at the first colonoscopy, more often reported a history of environmental allergies, eczema, asthma, and a family history of allergic and/or GI disease ( Table 1) .
Evaluation of Eosinophils per High-power Field in the Colon
We next assessed the peak mucosal eosinophils in those with colonic eosinophilia and normal controls at each section of the colon and compared the means of peak counts of different groups ( Fig. 1) . Patients with colonic eosinophilia had significantly greater mean numbers of eos/HPF in the cecum/ascending colon (colonic eosinophilia 56.0 AE 20.5, control 24.2 AE 10.2), transverse/descending (colonic eosinophilia 46.7 AE 23.1, control 18.8 AE 8.1), and rectosigmoid colon (colonic eosinophilia 43.2 AE 24.6, control 11.7 AE 7.1) P < 0.001 for differences in means for all locations. 
Diagnosis and Presentation of Colonic Eosinophilia
Patients with colonic eosinophilia presented with a variety of symptoms. The 3 most common of which included abdominal pain (59%), hematochezia (47%), and diarrhea (39%) ( (Fig. 2B ). Median follow-up was 12 months, range 0 to 84 months. Some patients had multiple diagnoses, which were not mutually exclusive. We next focused our assessment to understand differences between patients presenting with colonic eosinophilia who ultimately received diagnoses of IBD, EC, or other diagnoses.
Evaluation of Colonic Eosinophilia in Inflammatory Bowel Disease Versus Other Diagnoses
As a primary differentiating step, we compared colonic eosinophilia between patients with IBD and patients without IBD. We found that mean maximum eos/HPF were not significantly different between the two groups in the cecum/ascending colon (62.5 AE 20.3 vs 52.4 AE 20.0, P ¼ 0.078) or transverse/descending colon (53.9 AE 27.0 vs 42.6 AE 19.75, P ¼ 0.065), but were in the rectosigmoid colon (56.6 AE 28.1 vs 37.5 AE 20.9, P ¼ 0.0081). However, there was significant overlap between the 2 groups in all locations (Fig. 3) .
We next evaluated clinicopathologic factors in patients with final diagnoses of IBD versus other diagnoses ( Table 2 ). Significant differences between groups included: age at biopsy (P ¼ 0.0003), hemoglobin level (P ¼ 0.0217), with corresponding difference in hematocrit, ESR (P < 0.0001), percent of patients who presented with: hematochezia (P ¼ 0.0002), vomiting (P ¼ 0.0065), and signs of chronic colitis on initial biopsy (P < 0.001). Signs of chronic colitis on biopsy were the most sensitive marker for IBD with only 4 patients who did not have chronic changes on initial colonic biopsy who were diagnosed as having IBD. Three of these patients were diagnosed as having CD because of findings in the small bowel consistent with CD. We found that 41% of patients not diagnosed as having IBD had a concurrent diagnosis of EoE, whereas no patients with IBD met criteria for EoE (P ¼ 0.0001). No significant differences were found in sex, white blood cell count, peripheral blood eosinophil count, CRP, serum albumin, or presenting symptoms of diarrhea, abdominal pain, weight loss/poor weight gain, or location of eosinophils (confined to the lamina propria compared to infiltrating the epithelium and/or crypts). Finally (Supplemental Digital Content, Table, http:// links.lww.com/MPG/B185), we evaluated the relationship of number of eos/HPF to the same variables as in Table 2 and determined that patients with hematochezia and vomiting had significantly different numbers of eosinophils in the colon.
Comparison of Patients Without Inflammatory Bowel Disease, Eosinophilic Colitis/Eosinophilic Gastrointestinal Disease Versus All Other Diagnoses
As a secondary differentiating step, patients with colonic eosinophilia without IBD were further evaluated to attempt to FIGURE 1. Black error bar identifies mean peak eosinophils/HPF in control colonic (gray square) biopsies versus patients with colonic eosinophilia (black circle).
ÃÃÃÃ P < .0001. HPF ¼ high-power field. define their diagnoses ( 
Repeat Colonoscopy for Colonic Eosinophilia
We determined that 31 of 72 (43.1%) of the patients with colonic eosinophilia found on the initial colonoscopy had diagnoses that remained uncertain and/or continued to have clinical symptoms, and underwent a second colonoscopy (Fig. 4A) . Sixty-eight percent of patients who received !2 colonoscopies had a change in diagnosis (Fig. 4B) . Patients underwent the second colonoscopy on average 1.14 AE 0.96 years after the first colonoscopy. Analysis of this subgroup revealed that, after the first colonoscopy, 11 patients had an undefined diagnosis, 10 patients had diagnosis of IBD, and 7 had an original diagnosis of EGID/EC. After repeat colonoscopies, these numbers changed to 0 undefined, 14 with IBD, and 10 with EGID/EC, and 4 patients without signs or symptoms of colonic pathology (Fig. 4C ).
DISCUSSION
The aim of our study was to aid clinicians in understanding pediatric colonic eosinophilia. A major question in pediatrics is: how to define pathologic colonic eosinophilia, and can the number of eos/HPF delineate etiology? We found a significant difference in the mean of the peak eos/HPF in all locations in the colon between patients with colonic eosinophilia and controls. However, one novel aspect of our study is the significant variability found in controls and in children with colonic eosinophilia and the overlap of peak eos/HPF between control patients and those thought to have colonic eosinophilia. This variability likely contributes to the lack of consensus of normal versus abnormal eos/HPF. Different published studies have found FIGURE 3 . Peak eos/HPF by location in the colon in patients with colonic eosinophilia with diagnosis of IBD and without IBD (non-IBD). Differences in peak mean eos/HPF were significantly different in the rectosigmoid (P ¼ 0.008). eos/HPF ¼ eosinophils per high-power field; IBD ¼ inflammatory bowel disease.
ÃÃ Indicates P value. Patients with IBD were significantly older, had higher ESR, lower hemoglobin, more likely to have chronic inflammation on colonic biopsy, were less likely to present with vomiting, and less likely to have diagnosis of eosinophilic esophagitis. CRP ¼ C-reactive protein; ESR ¼ erythrocyte sedimentation rate; Hgb ¼ hemoglobin; HPF ¼ high-power field; IBD ¼ inflammatory bowel disease; N ¼ number of patients; SD ¼ standard deviation; WBC ¼ white blood cells. different numbers of eos/HPF in healthy children as well as a decrease in eos/HPF as one moves distally along the colon (1-3,18,19), which we have confirmed. As there is no consensus for pathologic colonic eosinophilia versus normal variation, we did not rely on a number cut-off to identify patients but rather pathologist interpretation of the biopsies as this is the situation frequently encountered by clinicians based on current knowledge. We were unable to define a clinically useful number cutoff for normal and abnormal eos/HPF given the significant overlap between our normal controls and patients with colonic eosinophilia. Any number chosen based on our sample would either misidentify many normal patients as abnormal or fail to identify many patients with pathologic colonic eosinophilia.
At first glance, our study appears to have different results for the control biopsies compared to a recent cohort of healthy Canadian children (4). Our numbers of mean peak eos/HPF of 24.2, 18.8, and 11.7 for the cecum/ascending, transverse/descending, and rectosigmoid colon, respectively, are approximately half those found in the Canadian study; however, the HPF area for their study was 0.55 mm 2 and our HPF area was roughly half at 0.26 mm 2 . Our study has similar results to DeBrosse et al (2006) (2) in the control subjects with their peak means 20.3, 16.3, and 8.3 for the ascending, transverse colon, and rectum, respectively. Their HPF area was 0.28 mm 2 . The slight difference in means is likely accounted for by the variation in healthy patients and slightly different biopsy locations between studies. This highlights 2 difficulties in interpreting eos/ HPF between published studies. The biopsy sites may be different, and there is no standardization for the area of HPFs. This places the responsibility on the clinician to confirm HPF area at their institution before interpreting eos/HPF results in relation to published studies, unless HPF areas can be standardized in the future. Overall, our analysis of control patients compared with those with colonic eosinophilia leads to the conclusion that eosinophils should be enumerated on biopsy reports to help guide the practitioner, but that the number of eos/HPF is not sufficient for diagnosis and other clinical factors must be considered.
We found 3 main groups of patients with colonic eosinophilia, which are important to distinguish: IBD, EC, and no significant colonic pathology. For the clinician, a major question that will guide future management for a patient with colonic eosinophilia is whether the child has IBD. IBD was diagnosed in 36% of patients in our sample, which is similar to what has been described previously (19) . The IBD group is characterized by an older age at presentation (mean 11.88 years vs 7.25) a significant inflammatory picture with elevated ESR, chronic inflammatory changes on colonic biopsy, and hematochezia. No single factor reliably predicted diagnosis of IBD, but the whole patient presentation was considered. Even chronic changes on initial biopsy were not specific, as 21.7% of patients without IBD had chronic changes on initial biopsy. Of these, 8 patients were diagnosed as having EC, Seven patients had resolution of lower abdominal complaints and/or resolution of colonic eosinophilia on repeat endoscopy but met criteria for EoE (EoE). Five patients had clinical course consistent with functional abdominal pain/IBS. Two patients had colonic eosinophilia but known histories of constipation and symptoms resolved with treatment of constipation. One patient had diarrhea as a toddler, which resolved with time and no intervention. Two patients had more rare colitites (collagenous and lymphocytic colitis). Two patients were lost to follow-up (family moved out of state) <4 weeks after endoscopy without leading diagnosis. EoE ¼ eosinophilic gastrointestinal disease; IBS ¼ irritable bowel syndrome.
as their biopsies were not classic for IBD given the eosinophilic predominance of their inflammation, 1 was diagnosed with collagenous colitis, and 1 had resolution of both chronic changes and colonic eosinophilia on repeat colonoscopies. We found that eos/ HPF, CRP, albumin, and weight loss were not reliable ways to identify patients with IBD. Unfortunately, too few of the patients we evaluated had fecal calprotectin testing performed making it impossible to analyze this as a diagnostic test to assist in the differentiation of IBD and other causes of colonic eosinophilia. Interestingly, patients with IBD were less likely to present with vomiting. This is likely related to 41% of patients in the non-IBD group also were diagnosed with EoE compared to none of the patients with IBD. This could help the clinician in that if a patient has colonic eosinophilia and meets criteria for EoE, it is unlikely that IBD is the underlying etiology, and primary EC or another etiology should be considered.
If a patient with colonic eosinophilia does not fit the clinical picture for IBD, the next important populations to distinguish are EC from other etiologies. We found that the factors associated with EC included higher peripheral eosinophil counts and male sex. These associations have previously been described in patients with EGIDs (20) (21) (22) and warrant additional studies. Twenty-one percent of patients identified with colonic eosinophilia did not have significant colonic pathology based on resolution of lower GI symptoms or normal histology on repeat colonoscopies. Again, this highlights that the number of eos/HPF alone is not a reliable indicator for underlying etiology and the whole clinicopathologic picture must be considered. As a significant proportion of patients with colonic eosinophilia may not have significant underlying colonic disease, the diagnostic and treatment approach must be tailored to the individual patient. Another consideration is that IBD may have years of quiescence between flares. It is possible that some patients who were identified as having colonic eosinophilia with subsequent symptomatic resolution may go on to develop more classic signs and histology of IBD in the future, but this would need to be evaluated in further long-term studies.
There were many patients for whom the diagnosis after initial colonoscopy was unclear or who had continued symptoms. This prompted 43% to undergo at least 1 additional colonoscopy. In these patients, the diagnosis significantly changed (unclear to more clear diagnosis, change of initial diagnoses to alternate diagnoses) in 68% of patients, and the percent of patients with !2 diagnoses being considered decreased to 0. In children, the decision to repeat an invasive procedure is not taken lightly given concern over neurodevelopmental effects of repeat or prolonged anesthesia episodes (23) (24) (25) , potential for adverse events, and significant cost. However, we conclude from our study that in patients with colonic eosinophilia in whom the diagnosis is unclear or who are not improving, repeat colonoscopy is a reasonable step, as in 2 of 3 of patients it can lead to a significant change in diagnosis and subsequent treatment.
Our study has several strengths it is the largest population of pediatric patients with colonic eosinophilia to be studied, the only one to compare controls to colonic eosinophilia, evaluate clinicopathologic findings associated with colonic eosinophilia and examine the utility of repeat colonoscopy. Limitations to this study include that it was performed in a single referral center for EGIDs and the study design was retrospective. In addition, we were unable to reliably determine use of medications at the time of colonoscopy. This study raises questions for future research including how to define pathologic colonic eosinophilia more reliably than eos/HPF. The lack of consensus on definition of pathologic colonic eosinophilia does not allow identification of a number cutoff of eos/HPF but rather the pathologist interpretation of increased eosinophils. We see from our population that choosing a number cutoff alone would not reliably differentiate normal from pathologic. Future research should move away from trying to define a normal number of eos/HPF and shift to focus on what other histologic factors may be a more reliable way to differentiate. Eotaxin staining, presence of eosinophil degranulation, and IL-5 staining are some possibilities. Until more reliable factors are identified, there will continue to be significant difficulty in defining pathologic colonic eosinophilia.
